For patients with chronic migraine that does not respond to treatment with topiramate, the use of Cefaly, a non-invasive neurostimulation device, proved to be a safe and effective option. Findings from this study were published online in the journal BMC Neurology.
Cefaly, a prescription-only FDA-approved device, is placed on the forehead for 20 minutes once daily and sends small electrical impulses through the skin to the trigeminal nerve to prevent episodic migraine attacks. The multi-center study enrolled patients diagnosed with chronic migraine who had previously failed treatment with topiramate.
Researchers observed patients for one month without using Cefaly, followed by three months of preventative treatment with only Cefaly. Results showed that after three months, the use of Cefaly was associated with a statistically significant, albeit small, reduction in the number of headache days, the number of headaches with intensity ≥5/10, and with use of acute medication (P<0.001 of all three). In addition, 65.7% (n=23) of patients said they were satisfied with the treatment and intended to continue using Cefaly.
Commenting on the study’s results, Dr. Pierre Rigaux, CEO of Cefaly Technology, said, “This is a great step that confirms Cefaly efficacy, particularly when medication fails, which is among the most difficult demographic of patients to treat.”
For more information visit Cefaly.us.